Back

Molecular and functional properties of human Plasmodium falciparum CSP C-terminus antibodies

Oludada, O. E.; Costa, G.; Burn Aschner, C.; Obraztsova, A.; Prieto, K.; Canetta, C.; Hoffmann, S. L.; Kremsner, P.; Mordmueller, B.; Murugan, R.; Julien, J.-P.; Levashina, E. A.; Wardemann, H.

2023-01-19 immunology
10.1101/2023.01.19.524692 bioRxiv
Show abstract

Human monoclonal antibodies (mAbs) against the central repeat and junction domain of Plasmodium falciparum circumsporozoite protein (PfCSP) have been studied extensively to guide malaria vaccine design compared to antibodies against the PfCSP C terminus. Here, we describe the molecular characteristics and protective potential of a panel of 73 germline and mutated human mAbs against the highly immunogenic PfCSP C-terminal domain. Two mAbs recognized linear epitopes in the C-terminal linker with sequence similarity to repeat and junction motifs, whereas all others targeted conformational epitopes in the -thrombospondin repeat (-TSR) domain. Specificity for the polymorphic Th2R/Th3R but not the conserved RII+ region in the -TSR was associated with IGHV3-21/IGVL3-21 or IGLV3-1 gene usage. Although the C terminus specific mAbs showed signs of more efficient affinity maturation and class-switching compared to anti-repeat mAbs, parasite inhibitory activity was limited to a single C-linker reactive mAb with cross-reactivity to the central repeat and junction. The data provide novel insights in the human anti-C-linker and anti--TSR antibody response that support exclusion of the PfCSP C terminus from malaria vaccine designs.

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

1
npj Vaccines
62 papers in training set
Top 0.1%
12.3%
2
Frontiers in Immunology
586 papers in training set
Top 0.5%
10.4%
3
Cell Reports Medicine
140 papers in training set
Top 0.4%
6.3%
4
JCI Insight
241 papers in training set
Top 0.5%
6.3%
5
Nature Communications
4913 papers in training set
Top 35%
4.3%
6
Science Translational Medicine
111 papers in training set
Top 0.6%
4.1%
7
eBioMedicine
130 papers in training set
Top 0.3%
3.6%
8
Scientific Reports
3102 papers in training set
Top 37%
3.6%
50% of probability mass above
9
PLOS Pathogens
721 papers in training set
Top 4%
3.6%
10
Cell Reports
1338 papers in training set
Top 15%
3.6%
11
The Journal of Immunology
146 papers in training set
Top 0.7%
2.1%
12
mBio
750 papers in training set
Top 6%
2.1%
13
PLOS ONE
4510 papers in training set
Top 48%
2.1%
14
Genome Medicine
154 papers in training set
Top 5%
1.7%
15
Journal of Clinical Investigation
164 papers in training set
Top 3%
1.7%
16
Molecular Therapy
71 papers in training set
Top 2%
1.7%
17
The Journal of Infectious Diseases
182 papers in training set
Top 3%
1.5%
18
EMBO Molecular Medicine
85 papers in training set
Top 2%
1.3%
19
Blood Advances
54 papers in training set
Top 0.9%
1.3%
20
eLife
5422 papers in training set
Top 49%
1.2%
21
BMC Medicine
163 papers in training set
Top 5%
0.9%
22
Vaccine
189 papers in training set
Top 2%
0.9%
23
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 41%
0.9%
24
The Lancet Infectious Diseases
71 papers in training set
Top 2%
0.9%
25
ACS Infectious Diseases
74 papers in training set
Top 1%
0.9%
26
Antibody Therapeutics
16 papers in training set
Top 0.5%
0.7%
27
Journal for ImmunoTherapy of Cancer
64 papers in training set
Top 1%
0.7%
28
iScience
1063 papers in training set
Top 32%
0.7%
29
Blood
67 papers in training set
Top 1%
0.7%
30
Journal of Thrombosis and Haemostasis
28 papers in training set
Top 0.8%
0.7%